The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Abstract
BACKGROUND: A consistent relationship between metabolic syndrome (MS) and myocardial infarction (MI) has been demonstrated. We evaluated the effect of bezafibrate retard, a fibric acid derivative, on the incidence of MI in patients with MS enrolled in the Bezafibrate Infarction Prevention (BIP) study. METHODS: Patients who displayed at least 3 of the following 5 risk factors were considered to have MS: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150 mg/dL (1.70 mmol/L); (3) a high-density lipoprotein cholesterol level less than 40 mg/dL (<1.04 mmol/L) in men or less than 50 mg/dL (<1.30 mmol/L) in women; (4) a systolic blood pressure of 130 mm Hg or diastolic blood pressure of 85 mm Hg; and (5) a body mass index of 28.0 kg/m(2). The study sample for this post hoc subgroup analyses comprised 1470 patients aged 42 to 74 years. The patients received either 400 mg of bezafibrate retard (740 patients) or placebo (730 patients) once a day. The mean follow-up period was 6.2 years for events and 8.1 years for mortality data. RESULTS: New MI was recorded in 193 patients: 82 (11.1%) of the 740 patients in the bezafibrate group vs 111 (15.2%) of the 730 patients in the placebo group (P = .02). Bezafibrate was associated with a reduced risk of any MI and nonfatal MI with hazard ratios (HRs) of 0.71 (95% confidence interval [CI], 0.54-0.95) and 0.67 (95% CI, 0.49-0.91), respectively. The cardiac mortality risk tended to be lower in patients taking bezafibrate (HR, 0.74; 95% CI, 0.54-1.03). In 575 patients with augmented features of MS (4-5 risk factors), the remarkable strengthening of cardiac mortality reduction when taking bezafibrate (HR, 0.44; 95% CI, 0.25-0.80) should be noted. CONCLUSION: Bezafibrate reduces the incidence of MI in patients with MS during long-term follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 3×
“nounced in patients who displayed baseline characteristics similar to MS definitions.(20,21) In the Bezafibrate Infarction Prevention (BIP) study,(25) no difference was apparent in the all-cause and cardiac mortality between the bezafibrate and placebo groups.”
BackgroundResultRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 3×
“nounced in patients who displayed baseline characteristics similar to MS definitions.(20,21) In the Bezafibrate Infarction Prevention (BIP) study,(25) no difference was apparent in the all-cause and cardiac mortality between the bezafibrate and placebo groups.”
BackgroundResultThe mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074 · cited 2×
“M ETABOLIC SYNDROME (MS), also known as dysmetabolic syndrome X, is a widespread overweightrelated clinical condition(1-4) that has an important cluster of atherothrombotic disease risk factors.(2-6) The inclusion of this syndrome in the Adult Treatment Panel III (ATPIII) guidelines(7) and the creation of an Internati…”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“Bezafibrate, compared with other fibrates, has a unique characteristic profile of action since it activates all 3 PPAR subtypes ( , , and ) at comparable doses.(42,43) Therefore, bezafibrate operates as a pan-agonist for all 3 PPAR isoforms.”
BackgroundThe deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Reaven, G. M., Lithell, H., & Landsberg, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602083340607 · Cited by 1,435 · cited 1×
“People who develop MS usually pass through the phases of excessive adipogenesis, nuclear peroxisome proliferator–activated receptor (PPAR) modulation, and insulin resistance.(10-14) The main components of MS are abdominal obesity, atherogenic dyslipidemia (elevated triglyceride levels, small low-density lipoprotein ch…”
BackgroundManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Ninomiya, J. K., L’Italien, G., Criqui, M. H., Whyte, J. L., Gamst, A., & Chen, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000108926.04022.0c · Cited by 793
Clustering of metabolic factors and coronary heart disease
Wilson, P. W. F., Kannel, W. B., Silbershatz, H., & D'Agostino, R. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1104 · Cited by 712
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Medical significance of peroxisome proliferator-activated receptors
Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 468
Epidemic Obesity and the Metabolic Syndrome
Haffner, S., & Taegtmeyer, H. (2003) · Circulation · doi:10.1161/01.cir.0000088845.17586.ec · Cited by 427
Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H., Sharp, P., Feher, M. D., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.641 · Cited by 271
Sacks, F. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02436-0 · Cited by 231
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Tenenbaum, A., Motro, M., Fisman, E. Z., Schwammenthal, E., Adler, Y., Goldenberg, I., Leor, J., Boyko, V., Mandelzweig, L., & Behar, S. (2004) · Circulation · doi:10.1161/01.cir.0000126824.12785.b6 · Cited by 174
Self-citationThe role of fibric acids in atherosclerosis
Fruchart, J.-C., Staels, B., & Duriez, P. (2001) · Current Atherosclerosis Reports · doi:10.1007/s11883-001-0015-x · Cited by 170
Jonkers, I. J., Mohrschladt, M. F., Westendorp, R. G., van der Laarse, A., & Smelt, A. H. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01123-8 · Cited by 166
Goldbourt, U., Behar, S., Reicher-Reiss, H., Agmon, J., Kaplinsky, E., Graft, E., Kishon, Y., Caspi, A., Weisbort, J., Mandelzweig, L., et al. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90905-r · Cited by 153
Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism
Fruchart, J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02149-x · Cited by 138
Insulin resistance: the fundamental trigger of type 2 diabetes
Groop, L. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.0010s1001.x · Cited by 137
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Tenenbaum, A., Fisman, E. Z., & Motro, M. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-4 · Cited by 112
Self-citationClinical interest of PPARs ligands
Vergès, B. L. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70083-6 · Cited by 112
Ericsson, C.-G., Nilsson, J. Å., Grip, L., Svane, B., & Hamsten, A. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00626-7 · Cited by 91
Jones, I. R., Swai, A. B. M., Taylor, R., Miller, M. A., Laker, M. F., & Alberti, K. G. M. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.8.855 · Cited by 90
Taniguchi, A., Fukushima, M., Sakai, M., Tokuyama, K., Nagata, I., Fukunaga, A., Kishimoto, H., Doi, K., Yamashita, Y., Matsuura, T., et al. (2001) · Metabolism · doi:10.1053/meta.2001.21028 · Cited by 59
Robins, S. J. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200312000-00005 · Cited by 52
Role of fibrates in reducing coronary risk: a UK Consensus
The UK HDL-C Consensus Group (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125002892 · Cited by 48
Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant, L. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263016 · Cited by 43
What to Do About the Metabolic Syndrome?
Hill, J. O., & Bessesen, D. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.395 · Cited by 35
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“20 mmol/L [151–155].”
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
Metadata
- Authors
- Tenenbaum, A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-23
- Volume
- 165
- Issue
- 10
- Pages
- 1154
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2156019168
- Cited by
- 311
- References
- 41
- FWCI
- 38.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.